A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations

导出原文传递

翻译打印收藏纠错

作者： Jordi Rodón ^[1] ; Pauline Funchain ^[2] ; Theodore W Laetsch ^[3] ; Hendrik-Tobias Arkenau ^[4] ; Alice Hervieu ^[5] ; Christian F Singer ^[6] ; Yonina R Murciano-Goroff ^[7] ; Sant P Chawla ^[8] ; Kristin Anthony ^[9] ; Ikuo Yamamiya ^[10] ; Mei Liu ^[11] ; Abdel-Baset Halim ; Karim A Benhadji ; Osamu Takahashi ; Suzette Delaloge

作者单位： Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer ^[1] Cleveland Clinic ^[2] Children's Hospital of Philadelphia, & University of Pennsylvania ^[3] Sarah Cannon Research Institute ^[4] Centre Georges-Fran?ois Leclerc ^[5] Dept of OB/GYN & Comprehensive Cancer Center, Medical University of Vienna ^[6] Memorial Sloan Kettering Cancer Center ^[7] Sarcoma Oncology Research Center ^[8] The PTEN Hamartoma Tumor Syndrome Foundation ^[9] Taiho Oncology ^[10] Institut Gustave Roussy ^[11]

关键词 advanced solid tumor clinical trial Cowden syndrome germline PTEN mutation PTEN hamartoma tumor syndrome PTEN inactivation TAS-117

发布时间 2023-03-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交